On this page you can find clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the drop-down lists below to find clinical trials by condition, status, phase and country.
Completed clinical trials may also have results available. If so, a simple summary of the overall results can be found on the lay summaries page.
You may also find a scientific summary of the results on the US and EU Clinical Trial Registries.
The ‘status’ of participant recruitment is defined as follows:
- Not yet recruiting – recruitment has not started yet
- Recruiting – recruitment is open
- Enrolling by invitation – recruitment is open to a particular population who are invited to participate.
- Active, not recruiting – recruitment is closed, participants are still ongoing in the clinical trial;
- Terminated – the study stopped early.
- Completed – the study ended.
Last Data Refreshed @ 29-Jul-2026 05:16:50 UTC
Filters
Condition
Status
Phase
Country
Showing 1 – 5 of 142 clinical trials
Acute Myeloid Leukemia
IPN60340
Japan
Austria
Korea (the Republic of)
Malaysia
New Zealand
Netherlands (Kingdom of the)
Poland
Belgium
Romania
Oman
France
Czechia
Bulgaria
Taiwan (Province of China)
Canada
China
Germany
Hungary
Greece
Denmark
Italy
Israel
Ireland
Hong Kong SAR China
Australia
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Switzerland
Turkey
Spain
Serbia
Not Yet Recruiting
A study to assess how well the study medicine IPN60340 works in combination with azacitidine and venetoclax, compared to placebo in combination with azacitidine and venetoclax, in participants with newly diagnosed acute myeloid leukemia who cannot receive intensive chemotherapy
The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with AML. Acute myeloid leukemia is a rare blood cancer that grows quickly. This study’s main aim is to compare the percentage of participants who reach complete remission within the first 6 months of treatment between the 2 study arms (study drug and standard medicines compared to placebo and standard medicines).
In this study all participants will receive AV plus either the study drug IPN60340 or placebo. Venetoclax will be given as a tablet by mouth once each day in 28-day cycles. Azacitidine will be given by injection under the skin (subcutaneously) or through the veins (intravenously) daily for the first 7 days of each 28-day cycle. IPN60340 or placebo (depending on which arm of the study the participant is assigned to) will be given through the veins (intravenously) on Day 1 of each 28-day cycle. There will be 4 periods in this study:
• A screening period (up to 28 days) to assess whether the participant can take part requiring at least 1 visit to the study center.
• A treatment period where all eligible participants will receive AV plus either the study drug IPN60340 or placebo. The study requires 8 visits for the first month followed by 1 visit every month until unacceptable toxicity, disease progression, death, participant’s withdrawal of consent, investigator decision to stop treatment, or study is prematurely terminated by the sponsor, whichever occurs first. Additional visits may be required based on clinical necessity.
• A safety follow-up period (at 28 days [±3 days] after the last dose of study medicine) to assess safety after participants have finished treatment.
• A long-term follow-up period where participants’ health will be monitored using a telephone call or clinic visit every 12 weeks until death, loss to follow-up, withdrawal of consent, or until the end of study, whichever occurs first.
Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), bone marrow aspirates (sampling of the liquid part of the bone marrow). Some participants (participants with childbearing potential) will also undergo pregnancy testing. All participants will also be asked to fill in questionnaires.
The time each participant will be in this study will vary based on how well the medicine works to treat the participant’s AML. Azacitidine and venetoclax plus either IPN60340 or placebo will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.
Advanced Solid Tumours
IPN01195
France
Italy
United States of America (the)
Spain
Recruiting
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours.
The participants in this study will have advanced solid tumours. ‘Advanced solid tumours’ refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.
The study consists of two phases, called phase I and phase II.
Phase I will be conducted in two parts:
Part A: Phase I Part A study (dose escalation) is designed to find the dose range showing activity on the tumour that can be tolerated by the participants by testing different doses of IPN01195.
Part B: Phase I Part B of the study (dose confirmation) will assess the ability of study drug to prevent, slow down, or stop the growth of tumours (abnormal cell growths that can lead to cancer) and how the body processes and responds to the study drug when administered in a “low dose” or “high dose” and further explore the safety and tolerability.
These parts will consist of the following periods:
A period to assess eligibility (screening period).
A treatment period that will require at least two visits for the first month followed by one visit every month. There will be also one visit, at the end of treatment, at 30 days after the last administration of study drug.
An assessment visit will be required every 6 weeks up to Week 24 and every 12 weeks thereafter to measure the tumour again and to assess how it is evolving, whether it is getting bigger, smaller, is stable or has gone away.
Based on the results obtained from phase I, a phase II extension study will be included through to an updated study plan, to further evaluate the study drug.
In both study phases, participants will undergo blood samplings, urine collections, physical examinations and clinical evaluations. They may continue some other medications, but the details need to be recorded.
Advanced Solid Tumour
Metastatic Solid Tumour
IPN01203
France
Canada
Spain
United States of America (the)
Recruiting
A study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumour activity of IPN01203 in adults with locally advanced or metastatic solid tumours exposed to immune checkpoint inhibitor therapies
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours.
Advanced solid tumours are cancers that can occur in various organs or tissues and have spread from their original site to nearby tissues or other parts of the body.
There will be two parts to this study:
Phase Ia: This part (called dose escalation) will find the dose range that shows activity against the tumour and can be tolerated by participants by testing different increasing doses of IPN01203. Phase Ib: This part (called dose optimisation) will assess the ability of the drug to prevent, slow down, or stop the growth of tumours and how the body processes and responds to the drug when given in “low dose” or “high dose.” It will also further explore the safety and tolerability.
An additional part (phase II) may be added to the study based on the results of phase Ia and phase Ib.
Each part will consist of the following periods:
A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre.
A treatment period where all eligible participants will receive IPN01203. Requires approximately 15 visits for the first 2 months followed by 3 visits every month from month 3 until unacceptable toxicity, disease progression, death, upon participant’s withdrawal of consent, investigator decision, or study termination by the sponsor, whichever occurs first.
There will also be one visit at the end of treatment (EoT), 30 days after the last administration of the study intervention or prior to the start of new anticancer treatment, whichever is earlier.
Additionally, there will be one visit (the safety follow-up visit) 90 days after the last administration of study intervention or prior to the start of new anticancer treatment, whichever is earlier.
In both parts of the study, participants will undergo blood sampling, urine collection, physical examinations and clinical evaluations. They may continue some other medications, but the details need to be recorded.
Each participant will be in this study until death or withdrawal from the study. IPN01203 will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.
Chronic Migraine
Episodic Migraine
corabotase
Canada
Czechia
France
Australia
Germany
Georgia
New Zealand
Japan
Korea (the Republic of)
Poland
United States of America (the)
Spain
United Kingdom of Great Britain and Northern Ireland (the)
Brazil
Recruiting
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers.
Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. “Headache days” are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. “Migraine days” occur when the headache displays clear migraine characteristics.
This study aims to determine:
The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM,
The right amount (dose) of IPN10200 to inject at each point,
The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines.
Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 42 weeks.
The study will consist of 3 periods:
A ‘screening period’ to assess whether the participant can take part in the study.
Step 1 is divided in two cohorts. The study will assess sequentially the safety of two doses of IPN10200, a lower dose in the cohort 1 and a higher dose in cohort 2. Participants will be administered with the study drug or placebo. The treatment is injected in muscles of the head, face and neck. The safety of participants is monitored throughout the 36 weeks at each cohort.
Step 2: In this step, new eligible participants will be divided into two groups based on their diagnosis (EM or CM). These groups will then be randomly assigned to one of three intervention groups: Dose A, Dose B, or a placebo. The intervention will be given in a series of injections in muscles of the head, face and neck. Participants will be monitored for both efficacy and safety until they complete the Week 36 visit (the end of study).
Cervical Dystonia
corabotase
Poland
Germany
Italy
France
Czechia
United Kingdom of Great Britain and Northern Ireland (the)
Spain
United States of America (the)
Recruiting
A study of IPN10200 for the treatment of cervical dystonia in adults
The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating CD in adults.
Cervical dystonia can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. Cervical dystonia is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role.
The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period.
The study will consist of two periods:
(1) A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit.
(2) A Treatment Period of 36 weeks.
On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck, and shoulders. Participants may continue some other medications, but details need to be recorded. There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study.
The total study duration for a participant will be up to 40 weeks (approximately 9 months).